Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Preoperative Investigations in Patients With Liver Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alan Patrick Ainsworth, Odense University Hospital
ClinicalTrials.gov Identifier:
NCT00408122
First received: December 5, 2006
Last updated: October 15, 2014
Last verified: October 2014
  Purpose

The aim of the study is to evaluate the diagnostic procedures emission tomography in combination with a CT scan (PET/CT) and endoscopic ultrasonography (EUS) in the preoperative evaluation of resectability of patients with primary or secondary liver cancers.


Condition Intervention
Primary Liver Cancer
Liver Metastasis
Procedure: PET/CT scan and EUS

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Positron Emission Tomography/ CT Scan, Endoscopic Ultrasono¬Graphy, and Laparoscopic Ultrasonography in the Preoperative Assess¬Ment of Resectability in Patients With Primary and Secondary Liver Cancer

Resource links provided by NLM:


Further study details as provided by Odense University Hospital:

Enrollment: 77
Study Start Date: January 2007
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

PAtients with liver tumors

Criteria

Inclusion Criteria:

  • all patients who are referred to The Department of Surgery, Odense University Hospital, for surgical treatment of suspected or biopsy proven primary or secondary liver cancer.

Exclusion Criteria:

  • age less than 18 years
  • patients who are not fit for liver surgery because of co-morbidity
  • patients for whom the extra investigations in the study are considered to give an increased risk because of co-morbidity such as

    • Patients with s-creatinin > 150 micromol/l
    • Patients who take peroral antidiabetic drugs or have a poorly regulated diabetes mellitus
  • patients who do not understand the patient information
  • patients who do not want to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00408122

Locations
Denmark
Dept of Surgery, Odense university Hospital
Odense, Denmark, 5000
Sponsors and Collaborators
Odense University Hospital
Investigators
Principal Investigator: Henning O Nielsen, MD, DMsc dept. of Surgery, Odense University Hospital
  More Information

No publications provided

Responsible Party: Alan Patrick Ainsworth, dr, Odense University Hospital
ClinicalTrials.gov Identifier: NCT00408122     History of Changes
Other Study ID Numbers: VF-20060109
Study First Received: December 5, 2006
Last Updated: October 15, 2014
Health Authority: Denmark: Ethics Committee

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on November 20, 2014